Novo Nordisk and Eli Lilly Move to Narrow Ozempic Lawsuit Claims in Multidistrict Litigation

Novo Nordisk and Eli Lilly are seeking to refine the scope of the litigation surrounding their medication, Ozempic, facing a multidistrict litigation (MDL). The defendants have filed a motion taking aim at the majority of the counts presented in the plaintiffs’ master long-form complaint. Interestingly, they are deferring their challenge to specific claims for a future time. For further details, visit the original article.